Corticotropin's Regulatory Status in Canada

Corticotropin has no approved status with Health Canada's Therapeutic Products Directorate (TPD) or Biologic and Radiopharmaceutical Drugs Directorate (BRDD). This differs from its FDA-approved status in the United States, where it carries labelling for multiple indications. Canada does not currently recognize corticotropin as a licensed therapeutic product for any indication.

This regulatory gap exists because:

  1. No manufacturer has submitted a New Drug Submission (NDS) to Health Canada seeking approval for corticotropin
  2. Health Canada applies different evidentiary standards than the FDA; some older drugs approved decades ago in the US have not undergone the re-evaluation process required in Canada
  3. Commercial considerations: The manufacturer of Acthar Gel has historically prioritized the US market, where the drug commands significantly higher prices

How Health Canada Regulates Peptides and Hormones

Peptide hormones like corticotropin fall under Canada's Therapeutic Products Act and are regulated as either drugs or biologic drugs depending on their origin and manufacture. Health Canada's framework requires:

  • Efficacy data: Manufacturer must submit clinical trial evidence demonstrating safety and efficacy
  • Quality documentation: Manufacturing standards, stability data, and purity assays
  • Risk-benefit assessment: Health Canada evaluates whether benefits outweigh risks for the stated indication
  • Comparative analysis: How the drug performs against existing treatments (like oral corticosteroids)

For a hormone like corticotropin, manufacturers typically submit data from clinical trials showing superiority or meaningful advantage over alternatives. In corticotropin's case, no manufacturer has pursued this pathway in Canada.

Approved Alternatives in Canada

Canadian patients with conditions for which corticotropin is used in the US have access to alternative treatments approved by Health Canada:

For Infantile Spasms

Infantile spasms (also called West syndrome) is corticotropin's strongest indication in the US. In Canada, physicians typically use:

  • Vigabatrin: A first-line seizure medication approved by Health Canada, with strong evidence in infantile spasms
  • Oral corticosteroids: Prednisone or other glucocorticoids, though evidence in this population is debated
  • Other anticonvulsants: Levetiracetam, valproate, and other agents approved for pediatric seizure disorders

For Multiple Sclerosis Relapses

Canadian MS patients experiencing acute relapses typically receive:

  • Intravenous methylprednisolone: The standard-of-care inpatient treatment for MS relapses, supported by multiple clinical guidelines
  • Oral prednisone: An alternative outpatient approach
  • Disease-modifying therapies: Interferons, monoclonal antibodies, and newer agents that reduce relapse frequency

For Nephrotic Syndrome

Canadian nephrologists manage nephrotic syndrome with:

  • Oral corticosteroids: Prednisone or prednisolone, first-line therapy
  • Immunosuppressive agents: Cyclophosphamide, mycophenolate, or calcineurin inhibitors
  • Supportive care: ACE inhibitors, diuretics, and anticoagulation when appropriate

Can Canadians Access Corticotropin Through Other Means?

There are limited, heavily restricted pathways:

Special Access Programme (SAP)

Health Canada's Special Access Programme permits physicians to request unapproved drugs for patients with serious conditions who have exhausted approved alternatives. The SAP is not a routine pathway and requires:

  • A licensed Canadian physician to submit a detailed request
  • Evidence that approved treatments have been tried or are unsuitable
  • Justification for why the specific unapproved drug is necessary
  • Manufacturer cooperation (corticotropin's manufacturer must be willing to supply it)

Important: The SAP is designed for compassionate use in individual cases, not as a general access route. Approvals are granted on a case-by-case basis and are not guaranteed.

Clinical Trials

If a Canadian or US-based clinical trial involving corticotropin is enrolling Canadian participants, patients may access the drug through the research protocol. You can search ClinicalTrials.gov or Canadian Clinical Trials databases to identify active trials.

Cross-Border or Online Purchase (Legal Risk)

This is not recommended. Importing corticotropin from the US or other countries without Health Canada approval is technically illegal for personal use. Border agents may confiscate the medication, and there are no regulatory guarantees about product quality, sterility, or authenticity. The risks—including infections from improperly handled injectables—are significant.

Why Corticotropin Remains Unapproved in Canada

Several factors explain this regulatory gap:

1. Evidentiary Burden While corticotropin was approved by the FDA decades ago (some indications under older regulatory standards), Health Canada requires modern-standard evidence for most new approvals. The evidence supporting many of corticotropin's 19 US labels is considered weak by current standards. A manufacturer seeking approval would need to either conduct new trials (expensive and time-consuming) or argue that older data meets contemporary standards—a difficult bar.

2. Generic Alternatives Exist Oral corticosteroids are available generically and inexpensively in Canada. For most of corticotropin's indications, oral steroids are considered comparable or equivalent. Health Canada is unlikely to prioritize approval of a more expensive, injectable alternative without clear clinical superiority.

3. Commercial Incentives Corticotropin's manufacturer has invested heavily in the US market, where insurance coverage and pricing power are highest. Pursuing Health Canada approval—which involves regulatory costs, manufacturing adjustments, and pricing pressures—is less attractive from a business perspective.

4. Ongoing Debate Over Clinical Value The medical community remains divided on whether corticotropin offers meaningful advantages beyond oral steroids for most indications. This clinical uncertainty reduces manufacturers' incentive to seek approval in additional jurisdictions.

Health Canada's Enforcement and Import Rules

Health Canada's Therapeutic Products Directorate maintains a list of unauthorized drugs. While individuals traveling to the US can bring back a limited personal supply of FDA-approved medications for personal use, corticotropin—as a prescription injectable—falls into a grey area. Health Canada advises against importing unapproved prescription drugs, and border officials have discretion to confiscate them.

Pharmacies in Canada cannot legally dispense corticotropin, and Canadian wholesalers cannot import it for distribution.

What This Means for Canadian Patients

If you have a condition for which corticotropin is used in the US:

  1. Consult a Canadian physician first: They can assess whether approved alternatives are suitable for your case
  2. Understand your options: Oral corticosteroids, anticonvulsants, immunosuppressants, or other approved agents may be equally effective
  3. Explore the Special Access Programme if your doctor believes corticotropin is uniquely necessary and alternatives have failed
  4. Avoid grey-market imports: The medical, legal, and safety risks outweigh potential benefits

Comparison to Other Peptide Hormones in Canada

For context, other peptide hormones have different approval statuses in Canada:

  • Semaglutide (GLP-1 agonist): Approved for diabetes and obesity
  • Oxytocin (posterior pituitary hormone): Approved for labor induction and milk letdown
  • Insulin (pancreatic hormone): Approved in multiple formulations

These approvals reflect manufacturers' investment in Canadian regulatory submissions and strong clinical evidence. Corticotropin's absence from this list highlights the role of both regulatory requirements and commercial incentives in drug availability.

Regulatory History and Future Prospects

Health Canada has not announced any pending review of corticotropin. Given the availability of cheaper alternatives, the modest evidence base for most indications, and manufacturer priorities, approval in Canada seems unlikely in the near term.

However, if new clinical evidence emerges demonstrating clear superiority of corticotropin for specific conditions (e.g., stronger data on immunomodulatory benefits via melanocortin receptors), a manufacturer could theoretically pursue approval. Currently, no such effort is underway.